No. |
DrugBank |
Drug (Description in trials) [Number of descriptions] |
KEGG DRUG * | KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 | Calcium | [25] Amorphous calcium carbonate; Ascal(r) / carbasalate calcium; Atorvastatin calcium; Calcitriol & calcium; Calcium; Calcium and cholecalciferol; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium channel blockers; Calcium channel blockers (amlodipine, azelnidipine); Calcium citrate; Calcium citrate with vitamin d2; Calcium gluconate; Calcium lactate; Calcium levofolinate; Calcium rosuvastatin; Calcium, dietary; Carbasalate calcium; Crestor tablets (calcium rosuvastatin) film-coated tablets; Crystalline calcium supplements; Ibandronate+alfacalcidol+calcium; Low molecular weight heparin calcium injection; Rosuvastatin calcium; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin); Vidofludimus calcium; | - |
- |
- |
[24] 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
2 | Calcium gluconate | [1] Calcium gluconate; | D00935 |
- |
- |
[3] 214, 215, 235 |
3 | Dexmedetomidine | [8] Dexmedetomidine; Dexmedetomidine 1; Dexmedetomidine 2; Dexmedetomidine 3; Dexmedetomidine and fentanyl; Dexmedetomidine group; Dexmedetomidine hydrochloride; Dexmedetomidine hydrochloride infusion; | D00514 D01205 |
[3] ADRA2A, ADRA2B, ADRA2C |
[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
[11] 2, 4, 6, 21, 34, 70, 113, 212, 215, 226, 280 |
4 | Dobutamine | [1] Dobutamine; | D00632 D03879 D03880 D03881 |
[1] ADRB1 |
[10] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
[3] 57, 58, 215 |
5 | Eplerenone | [1] Eplerenone; | D01115 |
[1] NR3C2 |
[1] Aldosterone-regulated sodium reabsorption |
[3] 75, 113, 215 |
6 | Fentanyl | [5] Dexmedetomidine and fentanyl; Fentanyl; Fentanyl citrate; Fentanyl transdermal patch; Transdermal fentanyl matrix, gabapentin; | D00320 D01399 |
[1] OPRM1 |
[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
[5] 46, 70, 85, 215, 231 |
7 | Fluorescein | [1] Fluorescein; | D01261 D02024 |
- |
- |
[3] 19, 97, 215 |
8 | Ketamine | [3] Ketamine; S-ketamine; S-ketamine & midazolam; | D00711 D08098 |
[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
[17] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
[6] 6, 13, 70, 113, 156, 215 |
9 | Losartan | [8] Lisinopril, losartan, and atorvastatin; Losartan; Losartan and atenolol or propranolol; Losartan bluefish 50 mg; Losartan potasico; Losartan potassium; Losartan tablets & qingremoshen granule; Sildenafil and losartan; | D00357 D08146 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[18] 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
10 | Potassium | [4] Losartan potassium; Potassium; Potassium sparing diuretic; Potassium supplement; | D08403 |
- |
- |
[9] 46, 66, 67, 98, 115, 167, 179, 215, 235 |
11 | Sodium citrate | [1] Sodium citrate; | D01781 D05855 |
- |
- |
[3] 214, 215, 235 |
12 | Tranexamic acid | [2] Tranexamic acid; Tranexamic acid 100 mg/ml; | D01136 |
[1] PLG |
[4] Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
[5] 46, 70, 215, 227, 288 |
13 | Ubidecarenone | - | D01065 |
- |
- |
[12] 2, 5, 6, 8, 10, 46, 57, 86, 113, 193, 214, 215 |